基于放射组学的脑转移瘤立体定向放射外科治疗反应预测流程的开发与验证
本研究纳入337例脑转移瘤患者,提取多模态MRI放射组学特征并结合临床特征构建两阶段级联模型预测立体定向放射外科治疗反应,最优模型在训练集AUC为0.95(95%CI 0.88-0.98),内部验证集AUC为0.93(95%CI 0.76-0.95),外部验证集AUC为0.90(95%CI 0.73-0.93)。
要点
- 多模态MRI放射组学联合临床特征可无创预测脑转移瘤对立体定向放射外科的治疗反应。
- 最优模型在训练集AUC 0.95,内部验证集AUC 0.93,外部验证集AUC 0.90。
- 多模态和多掩膜组合对预测有显著贡献,水肿指数也显示出一定预测价值。
核心结论
- 所提出的预测流程可无创预测脑转移瘤患者对立体定向放射外科治疗的反应,从而辅助医生精准制定个体化首次治疗决策。
研究设计与样本
- 研究纳入337例脑转移瘤患者,训练集277例、内部验证集30例、外部验证集30例;从9个ROI提取19377个放射组学特征(3个掩膜×3个MRI序列×2153个特征),经LASSO和mRMR算法筛选,结合4个临床特征,使用SVM和集成学习分类器构建两阶段级联模型。
诊断标准与关键数值
- 最优模型在训练集AUC为0.95(95%CI 0.88-0.98),内部验证集AUC为0.93(95%CI 0.76-0.95),外部验证集AUC为0.90(95%CI 0.73-0.93);模型性能通过准确率、特异度、敏感度和AUC曲线评估。
临床应用与阅片要点
- 所提出的预测流程可无创预测脑转移瘤患者对立体定向放射外科治疗的反应,辅助医生精准制定个体化首次治疗决策;多模态和多掩膜组合对预测有显著贡献,水肿指数也显示出一定预测价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The first treatment strategy for brain metastases (BM) plays a pivotal role in the prognosis of patients. Among all strategies, stereotactic radiosurgery (SRS) is considered a promising therapy method. Therefore, we developed and validated a radiomics-based prediction pipeline to prospectively identify BM patients who are insensitive to SRS therapy, especially those who are at potential risk of progressive disease.
METHODS: A total of 337 BM patients (277, 30, and 30 in the training set, internal validation set, and external validation set, respectively) were enrolled in the study. 19,377 radiomics features (3 masks × 3 MRI sequences × 2153 features) extracted from 9 ROIs were filtered through LASSO and Max-Relevance and Min-Redundancy (mRMR) algorithms. The selected radiomics features were combined with 4 clinical features to construct a two-stage cascaded model for the prediction of BM patients' response to SRS therapy using SVM and an ensemble learning classifier. The performance of the model was evaluated by its accuracy, specificity, sensitivity, and AUC curve.
RESULTS: Radiomics features were integrated with the clinical features of patients in our optimal model, which showed excellent discriminative performance in the training set (AUC: 0.95, 95% CI: 0.88-0.98). The model was also verified in the internal validation set and external validation set (AUC 0.93, 95% CI: 0.76-0.95 and AUC 0.90, 95% CI: 0.73-0.93, respectively).
CONCLUSIONS: The proposed prediction pipeline could non-invasively predict the response to SRS therapy in patients with brain metastases thus assisting doctors to precisely designate individualized first treatment decisions.
CLINICAL RELEVANCE STATEMENT: The proposed prediction pipeline combines the radiomics features of multi-modal MRI with clinical features to construct machine learning models that noninvasively predict the response of patients with brain metastases to stereotactic radiosurgery therapy, assisting neuro-oncologists to develop personalized first treatment plans.
KEY POINTS: • The proposed prediction pipeline can non-invasively predict the response to SRS therapy. • The combination of multi-modality and multi-mask contributes significantly to the prediction. • The edema index also shows a certain predictive value.
引用
- Du P, Liu X, Xiang R, et al. Development and validation of a radiomics-based prediction pipeline for the response to stereotactic radiosurgery therapy in brain metastases. Eur Radiol. 2023. PMID: 37505244. doi:10.1007/s00330-023-09930-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。